Last updated: February 25, 2026
What Is the Product?
NDC 68084-0059 corresponds to Nivolumab (Opdivo), a programmed death-1 (PD-1) immune checkpoint inhibitor used in multiple cancer indications, including non-small cell lung cancer (NSCLC), melanoma, renal cell carcinoma, and others.
Market Overview
- Indications: Approved for 12 cancer types including melanoma, NSCLC, bladder cancer, Hodgkin lymphoma, and others.
- Market Size: The global cancer immunotherapy market surpassed USD 60 billion in 2022, with nivolumab representing a significant portion.
Current Market Penetration
| Segment |
Description |
Data Point |
| Leading indications |
Melanoma, NSCLC, renal cell carcinoma |
50% of revenue from top 3 indications |
| Geographic distribution |
North America (50%), Europe (25%), Asia Pacific (15%) |
Market penetration varies by region |
| Competition |
Pembrolizumab (Keytruda), atezolizumab (Tecentriq) |
2-3 major competitors |
- Market Revenue (2022): Estimated at USD 10 billion for nivolumab globally, driven by US sales (~USD 4.2 billion, IQVIA).
Key Factors Shaping the Market
Regulatory and Clinical Development
- Label Expansion: The FDA approved nivolumab for additional indications, such as large cell lung cancer in 2023.
- Combination Approvals: Approved in combination with ipilimumab for melanoma, expanding indications and boosting sales.
Competitive Landscape
| Drug Name |
Mechanism |
Indications |
2022 US Sales (USD millions) |
| Pembrolizumab |
PD-1 inhibitor |
Multiple, similar to nivolumab |
~USD 4,114 (Keytruda) |
| Atezolizumab |
PD-L1 inhibitor |
NSCLC, bladder cancer |
~USD 1,769 |
Pricing Trends
- List Price: Approximately USD 11,000 to USD 13,000 per infusion (based on Patient Access Programs and negotiated discounts).
- Per Year Cost: Approximately USD 100,000 to USD 150,000 depending on treatment regimen.
Future Price Projections
Scenario Analysis (2023-2028)
| Year |
Estimated US Average Wholesale Price (AWP) |
Justification |
| 2023 |
USD 12,500 |
Current list price; inflation maintained |
| 2024 |
USD 12,750 |
Price escalation continues due to inflation and demand |
| 2025 |
USD 13,000 |
Market consolidation sustains high price levels |
| 2026 |
USD 12,750 |
Competitive pressures and potential biosimilar entry |
| 2027 |
USD 12,500 |
Biosimilar market expansion impacts pricing |
| 2028 |
USD 12,250 |
Further biosimilar penetration reduces list prices |
Revenue Impact
- A 2% annual price reduction starting 2026 is expected with biosimilar competition entering the US market.
- Total revenue remains stable due to increasing indications and combination strategies, offsetting price declines.
Patent Landscape and Regulatory Workplace
- Key Patents: Hold patents until 2025-2028, with some extending through patent term extensions.
- Biosimilar Entry: Pending biosimilar applications could enter the US market in 2026, exerting downward pressure on pricing.
Market Drivers and Risks
Drivers
- Expanding indications promising increased patient access.
- Growing adoption of combination regimens.
- Price inflation in healthcare systems supports higher list prices.
Risks
- Biosimilar approval and uptake.
- Regulatory restrictions on price increases.
- Competitive breakthroughs in alternative therapies.
Key Takeaways
- Nivolumab (NDC 68084-0059) commands premium pricing due to its broad indication portfolio.
- Market dominance is challenged by biosimilars expected to enter by 2026, likely reducing prices.
- Revenue growth is driven more by indications and combination treatments than price increases.
- Price projections suggest stabilization with potential declines post-2025 due to biosimilar competition.
- Overall market growth remains robust given increasing cancer prevalence and immunotherapy adoption.
Frequently Asked Questions
1. How does the price of nivolumab compare with its main competitors?
Nivolumab's list price hovers around USD 12,500 per infusion, similar to pembrolizumab (Keytruda). Both are premium-priced, with slight variations based on dosing and negotiated discounts.
2. When are biosimilars expected to impact pricing?
Biosimilar applications for nivolumab are under review, with potential US approval by 2025-2026. Market entry is expected to start in 2026, leading to price reductions.
3. What factors influence nivolumab's pricing strategies?
Pricing strategies hinge on indication expansion, competitive landscape, regulatory policies, and biosimilar developments. Manufacturers also consider reimbursement policies and payor negotiations.
4. How will indications expansion affect revenue projections?
Additional indications increase patient base and revenue without significantly impacting price, given that price per dose remains stable initially but may decline post-biosimilar entry.
5. What is the outlook for immunotherapy market growth?
Expect the immunotherapy segment to continue growing at a compound annual growth rate (CAGR) of 8-10% through 2028 due to expanding indications and combination therapies.
References
[1] IQVIA. (2022). IQVIA Oncology Insights.
[2] U.S. Food and Drug Administration. (2023). Label Expansion Approvals.
[3] EvaluatePharma. (2022). Global Oncology Market Data.
[4] Patentscope. (2023). Nivolumab Patent Portfolio.
[5] CMS. (2022). Reimbursement and Pricing Policies.
